Expert Interview
Reviewing the recent decision by Pfizer to remove OXBRYTA (voxelotor) for sickle cell disease from the market.
Ticker(s): PFE, FULCInstitution: Emory University
- Associate professor of pediatrics at Emory University.
- Currently manages ~150 patients with Sickle Cell Disease.
- Research focuses on the mechanisms of globin switching and the pharmacogenomics of hydroxyurea in SCD.
Can you provide background information on your expertise in sickle cell disease and details about your current practice, including how many patients with sickle cell you manage?
Added By: slingshot_insightsCould you discuss the standard care options available for sickle cell disease, and explain the role of treatments like hydroxyurea, transfusions, and gene therapy?
What has been your experience with gene therapies for sickle cell, including patient eligibility, necessary accreditations, and challenges in implementation?
Added By: slingshot_insightsCan you share insights on your experience with Pfizer’s Oxbryta, its effectiveness, safety concerns, and the implications of its recent market withdrawal?
Added By: slingshot_insightsHow are you managing patients who were on Oxbryta following its withdrawal, and what are the potential substitutes or alternative treatment options?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
